1-¬(3R)-Amino-4-(2-fluoro-phenyl)-butyl|-pyrrolidine-(2R)-carboxylic acid benzyl amine derivatives and related compounds as dipeptidyl peptidase IV (DPP-IV) inhibitors for the treatment of type 2 diabetes mellitus

(19)

(11)

EP 1 604 662 A8

(12)	CORRECTED EUROPEAN PATENT APPLICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 A1)

(48)	Corrigendum issued on:
	12.04.2006 Bulletin 2006/15

(43)	Date of publication:
	14.12.2005 Bulletin 2005/50

(21)	Application number: 04013510.5

(22)	Date of filing: 08.06.2004

(51)

International Patent Classification (IPC):

A61K 31/401^(2000.01)
A61K 31/472^(2000.01)
C07D 207/16^(1985.01)
C07D 207/08^(1985.01)
C07D 217/14^(1985.01)
C07D 241/04^(1985.01)

A61K 31/40^(1985.01)
A61K 31/495^(1985.01)
C07D 207/09^(1985.01)
C07D 217/26^(1985.01)
C07D 217/16^(1985.01)
A61P 3/10^(2000.01)

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR
	Designated Extension States:
	AL HR LT LV MK

(71)	Applicant: Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft
	69120 Heidelberg (DE)

(72)	Inventors:
	Edwards, Paul John 69115 Heidelberg (DE) Cerezo-Galvez, Silvia 42287 Wuppertal (DE) Feurer, Achim 69259 Wilhelmsfeld (DE) Matassa, Victor Giulio 69493 Hirschberg (DE) Nordhoff, Sonja 69198 Schrisheim (DE) Hill, Oliver 69239 Neckarsteinach (DE) Thiemann, Meinolf 69121 Heidelberg (DE) Lopez-Canet, Meritxell 69123 Heidelberg (DE)

(74)	Representative: Goldbach, Klara et al
	Grünecker, Kinkeldey, Stockmair & Schwanhäusser Anwaltssozietät Maximilianstrasse 58 80538 München 80538 München (DE)

(54)	1-¬(3R)-Amino-4-(2-fluoro-phenyl)-butyl\|-pyrrolidine-(2R)-carboxylic acid benzyl amine derivatives and related compounds as dipeptidyl peptidase IV (DPP-IV) inhibitors for the treatment of type 2 diabetes mellitus

(57) The invention relates to compounds of formula (I)

wherein R^1-9, Z, n, X, A, and R^b have the meaning as cited in the description and the claims. Said compounds are useful as DPP-IV inhibitors. The invention also relates to the preparation of such compounds as well as the production and use thereof as medicament for the treatment of type 2 diabetes mellitus, obesity and lipid disorders.